AUA 2021: Padeliporfin Is Promising for Partial Gland Ablation of Intermediate-Risk Prostate Cancer
The therapy curbs progression and minimizes need for radical treatment.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.